Cargando…
Non-apoptotic activity of the mitochondrial protein SMAC/Diablo in lung cancer: Novel target to disrupt survival, inflammation, and immunosuppression
Mitochondrial SMAC/Diablo induces apoptosis by binding the inhibitor of apoptosis proteins (IAPs), thereby activating caspases and, subsequently, apoptosis. Previously, we found that despite its pro-apoptotic activity, SMAC/Diablo is overexpressed in cancer, and demonstrated that in cancer it posses...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515501/ https://www.ncbi.nlm.nih.gov/pubmed/36185255 http://dx.doi.org/10.3389/fonc.2022.992260 |
_version_ | 1784798496200589312 |
---|---|
author | Pandey, Swaroop Kumar Shteinfer-Kuzmine, Anna Chalifa-Caspi, Vered Shoshan-Barmatz, Varda |
author_facet | Pandey, Swaroop Kumar Shteinfer-Kuzmine, Anna Chalifa-Caspi, Vered Shoshan-Barmatz, Varda |
author_sort | Pandey, Swaroop Kumar |
collection | PubMed |
description | Mitochondrial SMAC/Diablo induces apoptosis by binding the inhibitor of apoptosis proteins (IAPs), thereby activating caspases and, subsequently, apoptosis. Previously, we found that despite its pro-apoptotic activity, SMAC/Diablo is overexpressed in cancer, and demonstrated that in cancer it possesses new essential and non-apoptotic functions that are associated with regulating phospholipid synthesis including modulating mitochondrial phosphatidylserine decarboxylase activity. Here, we demonstrate additional functions for SMAC/Diablo associated with inflammation and immunity. CRISPR/Cas9 SMAC/Diablo-depleted A549 lung cancer cells displayed inhibited cell proliferation and migration. Proteomics analysis of these cells revealed altered expression of proteins associated with lipids synthesis and signaling, vesicular transport and trafficking, metabolism, epigenetics, the extracellular matrix, cell signaling, and neutrophil-mediated immunity. SMAC-KO A549 cell-showed inhibited tumor growth and proliferation and activated apoptosis. The small SMAC-depleted “tumor” showed a morphology of alveoli-like structures, reversed epithelial-mesenchymal transition, and altered tumor microenvironment. The SMAC-lacking tumor showed reduced expression of inflammation-related proteins such as NF-kB and TNF-α, and of the PD-L1, associated with immune system suppression. These results suggest that SMAC is involved in multiple processes that are essential for tumor growth and progression. Thus, targeting SMAC’s non-canonical function is a potential strategy to treat cancer. |
format | Online Article Text |
id | pubmed-9515501 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95155012022-09-29 Non-apoptotic activity of the mitochondrial protein SMAC/Diablo in lung cancer: Novel target to disrupt survival, inflammation, and immunosuppression Pandey, Swaroop Kumar Shteinfer-Kuzmine, Anna Chalifa-Caspi, Vered Shoshan-Barmatz, Varda Front Oncol Oncology Mitochondrial SMAC/Diablo induces apoptosis by binding the inhibitor of apoptosis proteins (IAPs), thereby activating caspases and, subsequently, apoptosis. Previously, we found that despite its pro-apoptotic activity, SMAC/Diablo is overexpressed in cancer, and demonstrated that in cancer it possesses new essential and non-apoptotic functions that are associated with regulating phospholipid synthesis including modulating mitochondrial phosphatidylserine decarboxylase activity. Here, we demonstrate additional functions for SMAC/Diablo associated with inflammation and immunity. CRISPR/Cas9 SMAC/Diablo-depleted A549 lung cancer cells displayed inhibited cell proliferation and migration. Proteomics analysis of these cells revealed altered expression of proteins associated with lipids synthesis and signaling, vesicular transport and trafficking, metabolism, epigenetics, the extracellular matrix, cell signaling, and neutrophil-mediated immunity. SMAC-KO A549 cell-showed inhibited tumor growth and proliferation and activated apoptosis. The small SMAC-depleted “tumor” showed a morphology of alveoli-like structures, reversed epithelial-mesenchymal transition, and altered tumor microenvironment. The SMAC-lacking tumor showed reduced expression of inflammation-related proteins such as NF-kB and TNF-α, and of the PD-L1, associated with immune system suppression. These results suggest that SMAC is involved in multiple processes that are essential for tumor growth and progression. Thus, targeting SMAC’s non-canonical function is a potential strategy to treat cancer. Frontiers Media S.A. 2022-09-14 /pmc/articles/PMC9515501/ /pubmed/36185255 http://dx.doi.org/10.3389/fonc.2022.992260 Text en Copyright © 2022 Pandey, Shteinfer-Kuzmine, Chalifa-Caspi and Shoshan-Barmatz https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Pandey, Swaroop Kumar Shteinfer-Kuzmine, Anna Chalifa-Caspi, Vered Shoshan-Barmatz, Varda Non-apoptotic activity of the mitochondrial protein SMAC/Diablo in lung cancer: Novel target to disrupt survival, inflammation, and immunosuppression |
title | Non-apoptotic activity of the mitochondrial protein SMAC/Diablo in lung cancer: Novel target to disrupt survival, inflammation, and immunosuppression |
title_full | Non-apoptotic activity of the mitochondrial protein SMAC/Diablo in lung cancer: Novel target to disrupt survival, inflammation, and immunosuppression |
title_fullStr | Non-apoptotic activity of the mitochondrial protein SMAC/Diablo in lung cancer: Novel target to disrupt survival, inflammation, and immunosuppression |
title_full_unstemmed | Non-apoptotic activity of the mitochondrial protein SMAC/Diablo in lung cancer: Novel target to disrupt survival, inflammation, and immunosuppression |
title_short | Non-apoptotic activity of the mitochondrial protein SMAC/Diablo in lung cancer: Novel target to disrupt survival, inflammation, and immunosuppression |
title_sort | non-apoptotic activity of the mitochondrial protein smac/diablo in lung cancer: novel target to disrupt survival, inflammation, and immunosuppression |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515501/ https://www.ncbi.nlm.nih.gov/pubmed/36185255 http://dx.doi.org/10.3389/fonc.2022.992260 |
work_keys_str_mv | AT pandeyswaroopkumar nonapoptoticactivityofthemitochondrialproteinsmacdiabloinlungcancernoveltargettodisruptsurvivalinflammationandimmunosuppression AT shteinferkuzmineanna nonapoptoticactivityofthemitochondrialproteinsmacdiabloinlungcancernoveltargettodisruptsurvivalinflammationandimmunosuppression AT chalifacaspivered nonapoptoticactivityofthemitochondrialproteinsmacdiabloinlungcancernoveltargettodisruptsurvivalinflammationandimmunosuppression AT shoshanbarmatzvarda nonapoptoticactivityofthemitochondrialproteinsmacdiabloinlungcancernoveltargettodisruptsurvivalinflammationandimmunosuppression |